Recombinant Human Beta-defensin 4A protein (DEFB4A) (Active)

This Recombinant Human DEFB4A protein serves as an essential tool for investigators in the field of microbiology. The Defensin beta 4A, also known as DEFB4A, is expressed in E. coli, featuring the 24-64aa expression region of the full-length mature protein. The tag-free protein is provided as a lyophilized powder, allowing for straightforward reconstitution with sterile water or buffer to facilitate a wide range of experimental applications.

With a commitment to quality and performance, our Recombinant Human DEFB4A protein exhibits a purity of >98% as determined by SDS-PAGE and HPLC analysis. Furthermore, endotoxin levels are maintained below 1.0 EU/µg, as assessed by the LAL method. The protein demonstrates full biological activity in a chemotaxis bioassay using immature human dendritic cells, with an effective concentration range of 10-100 ng/ml.

Human DEFB4A has been the focus of numerous studies due to its role in host defense and antibacterial properties. Semple et al. (2010)^[1] and Harder et al. (2007)^[2] reported on the antimicrobial and immunomodulatory functions of DEFB4A. In addition, Hancock et al. (2016)^[3] discussed its potential as a therapeutic agent for the treatment of infectious diseases. These studies highlight the importance of DEFB4A in the innate immune system and its potential as a therapeutic target.

References:
1. Semple F, et al. Beta-defensins: multifunctional modulators of infection, inflammation and more? J Innate Immun. 2010;4(4):337-48.
2. Harder J, et al. An update on human defensins. Arch Immunol Ther Exp (Warsz). 2007;55(2):85-98.
3. Hancock REW, et al. The immunology of host defence peptides: beyond antimicrobial activity. Nat Rev Immunol. 2016;16(5):321-34.